Pfizer Considers Sale of Acquired Hospira Devices Biz

Source: Bloomberg

Jan 14, 2016

Pfizer is considering a sale of the pumps and devices business it acquired in last year’s purchase of Hospira, says Bloomberg sources.

Sources say the NY-based drugmaker is in the early stages of a deal that could be worth around $2 billion.

Last February, Pfizer announced that it had acquired Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for approximately $17 billion.

According to analysts, selling the devices business would leave Pfizer a more pure-play drugs unit for a possible spinoff.

Read the Bloomberg article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments